Paxalisib better than Temozolomide?
Paxalisib's mechanism of action involves directly suppressing PI3K in the PI3K/AKT kinase (also known as protein kinase B) signalling pathway, which prevents the PI3K signalling pathway from being activated. In sensitive tumour cell populations, this may prevent both cell growth and survival.
When used as first-line therapy in individuals with glioblastoma, paxalisib Phase II results from Kazia Therapeutics are comprehensive and contain interesting sensitivity analysis. In this single-arm research, paxalisib was administered as monotherapy to all 30 evaluable patients with newly diagnosed glioblastoma with unmethylated MGMT promotor status. According to the study, temozolomide had a median overall survival of 15.7 months while the median overall survival for patients who had previously received treatment was 12.7 months. Furthermore, according to the RANO criteria, the median progression-free survival (mPFS) was 8.6 months, a significant improvement above the 5.3 months linked to temozolomide. Kazia Therapeutics' profile paxalisib (safety) was quite consistent with earlier clinical investigations.
The updated data, which was presented at ASCO today, "provides a more comprehensive view of the trial and also includes some useful sensitivity assessments." - Expert Verdict.
Conclusion
With regard to newly diagnosed glioblastoma patients, paxalisib anticipates a dramatic shift in the therapeutic paradigm given the encouraging results of its Phase II data. But let's not lose sight of the fact that GBM is a very tough nut to crack given the aggressiveness of the illness and the dismal survival rate. Bevacizumab has been approved for recurrent GBM patients for years, however it has not been successful in first-line GBM treatment (except in Japan). However, paxalisib looks to provide better hope for safety and tolerability in patients with recently diagnosed glioblastoma.
The GBM market is currently experiencing some activity in the ASCO 2022, with SurVaxM (MimiVax) demonstrating promising results and paxalisib now demonstrating its promise in the first-line context. Other important GBM treatments, including Regorafenib (Bayer), Durvalumab (MEDIMMUNE/AstraZeneca), and ONC-201, are in development (Chimerix).
Newly Diagnosed Glioblastoma Companies- Aivita Biomedical, Inc., Inovio Pharmaceuticals, Denovo Biopharma, IMVAX, Merck Sharp & Dohme Corp. and Eisai, MimiVax, Bristol-Myers Squibb, Novartis Pharmaceuticals.
Get in touch with our Business Expert @ Business Consulting Services | Biotech Consulting | Technical Due Diligence Firms
Trending & Popular Market Research Reports 2022 by Delveinsight
Reactive Airway Disease Market
Reactive Airway Disease Market report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends in the 7MM
Coronary Microvascular Dysfunction CMD Market
DelveInsight’s Coronary Microvascular Dysfunction Market Insights, Epidemiology, & Market Forecast 2032 report delivers an in-depth understanding of the CMD epidemiology & CMD market trends
Familial Lipoprotein Lipase Deficiency Pipeline
Familial Lipoprotein Lipase Deficiency Pipeline Insights, 2022 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across.
Pediatric Growth Hormone Deficiency PGHD Market
Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast report delivers an understanding of the Pediatric Growth Hormone Deficiency forecasted epidemiology
DelveInsight’s Shigellosis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Shigellosis, historical and forecasted epidemiology
About ASCO 2022 Conference Updates
asco 2021 highlights | asco highlights 2021 | asco medical conference | asco 2021 | asco 2021 conference | when is asco 2021 | 2021 asco | 2021 asco annual meeting | asco convention | asco conference 2021 | asco 2021 | asco 21 | asco us | asco 2022 annual meeting | asco abstract 2022
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash
info@delveinsight.com
